sitive C-reactive protein, fibrinogen, and leukocyte count and the CYP2J2 genotype. The CAD status was included as main effect, and statistical adjustments were made for age, sex, and cardiovascular risk factors (body mass index, diabetes mellitus, hypertension, and smoking). None of these models revealed any statistically significant relationships between the CYP2J2 genotype and inflammatory markers (data not shown).
In contrast to a recent study (3 ), we could not confirm the Ϫ50GϾT polymorphism as a risk factor for CAD or MI in our large cross-sectional LURIC cohort. In addition, we were not able to detect any relationship of this polymorphism with total mortality or cardiovascular mortality in this cohort at intermediate risk of death. Association studies of genetic polymorphisms often lead to discrepant results, especially if small numbers of cases and controls are examined. Therefore, the validity of genetic association studies using single nucleotide polymorphisms has recently been challenged (5 (1) (2) . Clinically, the testing of microalbuminuria uses immunochemical methods. Controversy exists, however, regarding the accuracy of immunochemical and chromatographic methods for quantifying urine albumin (3 ). We earlier reported on liquid chromatographymass spectrometry (LC-MS) for measurement of urinary albumin with bovine serum albumin (BSA) as an internal standard (4 ) . We now report the preparation of 15 N-labeled albumin as an internal standard and the validation of its use in an LC-MS assay for quantifying low concentrations of albumin in the urine of patients.
The Pichia pastoris strain GS115/ His ϩ Mut s (Invitrogen) was used to synthesize 15 N-labeled human serum (Fig. 1, A-C) . These fragments are consistent with b-series fragment ions originating from the N-terminus of the HSA molecule.
To certify the purity of the 15 Nlabeled HSA, we compared the source-induced-fragmentation spectrum (specifically the b 24 ϩ4 ions) of labeled HSA with the coinciding ion obtained from commercial HSA (Fig. 1, D and E) . For unlabeled HSA, the lowest expected mass for the isotope cluster of this ion was observed at the expected mass of m/z ϭ 684.6152. For the labeled material, the signal at this mass vanished and a signal was observed at m/z ϭ 693.3276, indicating virtually complete 15 N-labeling of the 35 nitrogens in the b 24 fragment. Calculations indicated that each individual nitrogen in the protein was 98.95% 15 N-labeled.
Because of low throughput, the Q-TOF mass spectrometer is not practical for routine clinical testing. Therefore, for routine clinical use, we validated the method using an API 5000™ triple quadrupole mass spectrometer (Applied Biosystems). Since tuning values of the API 5000 differ from those of the Q-TOF, the method was further optimized for the API 5000. The N-terminal fragment ions 3ϩ (m/z ϭ 924.1). The chromatographic conditions were the same as described earlier (4 ) .
Our precision studies yielded intraassay CVs (n ϭ 20) of 12.6% (17 mg/L), 10.1% (70 mg/L), and 4.0% (210 mg/L), and the interassay CVs (n ϭ 10) were 12.2% (19 mg/L), 11.0% (80 mg/L), and 7.1% (230 mg/ L). By running 20 replicate blanks we determined that the lowest analyte concentration indistinguishable from the blank was 2.5 mg/L. By running 20 replicates of a 5 mg/L sample, we established the limit of detection, defined as the lowest analyte concentration that can be distinguished from blank with Ͼ95% certainty, as 4.84 mg/L. The limit of quantification/functional sensitivity was set at 10.5 mg/L, corresponding to the lowest control patient samples with an interassay CV Ͻ20%.
Multiple calibration curves ranging from 4 to 625 mg/L were linear and were reproducible with the following linear regression equation: y ϭ 0.01x ϩ 0.20 (r 2 ϭ 0.999). The linearity of the assay was assessed by extracting 5 patient samples at the following serial dilutions: undiluted, 1:2, 1:4, and 1:8. The expected value for each sample was calculated based on the result obtained for the undiluted sample. The percentages of the expected results were 87%-121% (mean 98%) for urine specimens containing 80 -207 mg/L albumin. In additional experiments, HSA was added at 3 concentrations (40, 80, and 170 mg/L) into patient samples (n ϭ 5) and assayed in single determinations. For individual samples, calculated recoveries ranged from 93% to 117% (mean 105%). The comparison shows that the LC-MS method using 15 N-HSA is largely in agreement with the Hitachi method (y ϭ 0.96x ϩ 7.25, R 2 ϭ 0.99), similar to when BSA was employed as the internal standard. In conclusion, we have developed a sensitive and specific LC-MS assay for detection and measurement of urinary albumin that employs 15 N-HSA as a unique and novel internal standard.
